Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic and disease characteristics of patients with axial spondyloarthritis (axSpA) and patients with chronic back pain (CBP) participating in the SPACE cohort

From: Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort

  Diagnosed with axSpA  
Yes (n = 274) No (n = 286) P value
Male (n, %) 119 (43.4) 181 (28.3) <0.001
Age (mean, SD) 30.7 (7.9) 31.4 (8.5) 0.83
HLA-B27 positive (n, %) 165 (60.7) 63 (22.1) <0.001
Positive family history (n, %) 131 (47.8) 111 (38.8) 0.03
Duration of back pain in months (mean, SD) 13.1 (7.0) 13.5 (7.2) 0.59
Inflammatory back pain (n, %) 213 (77.7) 154 (54.0) <0.001
Peripheral arthritis (n, %) 59 (21.6) 23 (8.1) <0.001
Enthesitis (n, %) 91 (33.2) 21 (7.3) <0.001
Dactylitis (n, %) 25 (9.1) 4 (1.4) <0.001
IBD (n, %) 21 (7.7) 16 (5.6) 0.32
Psoriasis (n, %) 43 (15.7) 19 (6.6) 0.001
Uveitis (n, %) 32 (11.7) 7 (2.4) <0.001
Tender joint count (mean, SD) 2.2 (5.0) 1.9 (3.7) 0.38
Swollen joint count (mean, SD) 0.6 (2.1) 0.1 (0.6) 0.001
CRP, mg/L (median, IQR) 3.0 (3.0–5.0) 3.7 (3.0–7.0) 0.001
CRP >5 mg/L (n, %) 113 (41.7) 70 (26.2) <0.001
ESR, mm/h (mean, SD) 14.9 (15.8) 9.2 (11.4) <0.001
ESR >20 mm/h (n, %) 63 (23.6) 20 (7.1) <0.001
ASAS axSpA criteria (n, %) 172 (62.8) 48 (16.8) <0.001
mNY criteria (n, %) 33 (14.4) 5 (2.0) <0.001
Any DMARD use (n, %) 38 (14.0) 14 (5.1) <0.001
NSAID use (n, %) 197 (72.4) 172 (60.8) 0.004
BASDAI (mean, SD) 4.2 (2.1) 4.7 (2.0) 0.01
Diagnosed with axSpA at 1-year follow up (n, %) 143 (52.2) 16 (5.6) <0.001
  1. Missing values were below 5% except for axial spondyloarthritis (axSpA) diagnosis (5.6%), SJC (5.7%), C-reactive protein (CRP) (7.1%), modified New York (mNY) criteria (17.3%), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (15.0%) and the number of patients still diagnosed as having axSpA after 1 year of follow up (58.9%)
  2. ASAS Assessment of SpondyloArthritis International Society, DMARD disease-modifying antirheumatic drug, ESR erythrocyte sedimentation rate, IBD inflammatory bowel disease, NSAID nonsteroidal anti-inflammatory drug